AEROLATE III
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AEROLATE III (AEROLATE III).
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
| Metabolism | Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics. |
| Excretion | Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other |
| Half-life | Terminal half-life 12-15 hours; clinically allows twice-daily dosing |
| Protein binding | 92-96%, primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd 1.5-2.0 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral: 40-50%; Inhalation: 20-30% |
| Onset of Action | Oral: 30-60 minutes; Inhalation: 5-15 minutes |
| Duration of Action | Oral: 8-12 hours; Inhalation: 4-6 hours |
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No adjustment needed for GFR >30 mL/min. For GFR 10-30 mL/min: use 50% of usual dose. For GFR <10 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use. |
| Pediatric use | Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult. |
| Geriatric use | No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AEROLATE III (AEROLATE III).
| Breastfeeding | Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity. |
| Teratogenic Risk | AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/mL). Avoid near term due to prolonged neonatal half-life. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
| Precautions | Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/mL; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others. |
| Food/Dietary | Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum theophylline levels (therapeutic range 10-20 mcg/mL, lower end in pregnancy). Assess fetal heart rate and growth with ultrasound. Monitor for maternal tachycardia, palpitations, and signs of toxicity. |
| Fertility Effects | No direct evidence of adverse effects on fertility in humans. In animal studies, theophylline did not impair fertility at clinically relevant doses. |
| Clinical Pearls | AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/mL). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias. |
| Patient Advice | Take this medication exactly as prescribed; do not crush or chew extended-release tablets. · Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia. · Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures. · Do not stop taking this medication abruptly; taper under medical supervision. · Keep all appointments for blood tests to monitor theophylline levels. · Avoid smoking or using nicotine products, as they affect how the medication works. · Carry a list of all medications you take, as many can interact with theophylline. |